Abiopharma

🔍 Jaen Juan C. (Executive)

Company: Arcus Biosciences, Inc. (RCUS)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Sold 29,670 shares of Common Stock at $21.34 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 924,393.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,053 shares of Common Stock at $22.34 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 922,340.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 100 shares of Common Stock at $23.2 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 922,240.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-05 | Code: H | shares_owned_after: 346,012.00 | Footnotes: F4

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.
• F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F4: Includes the unvested portion of the reporting person's RSU grants.